Mastek Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/r1ic48f9a7k0c06noxzlq9mh.pdf

Key Takeaways


Revenue Growth: The Organic vs Inorganic Story

Hiral Chandrana: "The demand is cautious, but we see some really strong momentum in larger integrated deals."

UK Public Sector: The Moat Business

Hiral Chandrana: "We actually believe that it is going to get very tough for new competition to come in some of these areas that we are present in."

US Business: The Slow-Building Growth Engine

Hiral Chandrana: "It has taken longer than we expected, to be frank, because when we structure our teams, we're looking at client partner, program management, delivery management, and different rhythm when it comes to some of these enterprise accounts and larger customers."

Margins: Pressure Today, Recovery Promised Tomorrow

Arun Agarwal: "Currently, we believe, there is a more than enough rooms and opportunity to improve margin profile and we expect those improvement to start reflecting from Q4 onwards."

Healthcare & Vertical Mix

Hiral Chandrana: "I would say, this is probably like a bottom level on that mix. We will continue to see going forward hopefully we can get to almost 30% of our business from healthcare and life sciences."

Strategic Direction: The Billion-Dollar Ambition

Hiral Chandrana: "What we're trying to do is what Mastek has done in 40-years from a timeframe perspective is to do that in the next four years."

Guidance & Commitments

CommitmentSpecificsTimeline
Margin recoveryImprovement to start reflecting from Q4 onwards, subject to currencyQ4 FY23 onwards
US growth visibilityQuarter-on-quarter and year-on-year growth expectedH2 FY23
Healthcare mix recoveryCurrent mix is a bottom; target to reach 30% of businessFY26
Top-3 growth rate ambitionAmong top 10 in mid-market space; already tracked internallyFY25-26
Billion-dollar revenueCombination of organic and inorganicEarly second half of the decade
Account metric reportingRevenue from top 25/50 accounts and >Rs.100 crore accounts to be reportedGoing forward

Key Metrics

MetricQ2 FY23
Revenue₹625 cr, up 20.4% YoY and 10.7% QoQ in constant currency
Operating EBITDA17.2%
PAT₹86.2 cr, up 2.2% QoQ; includes exceptional items from property sale and acquisition costs
Gross cash₹352 cr, versus ₹665 cr in Q1 FY23
Borrowings₹388 cr as of 30 Sep, includes funds for MST acquisition
US revenue share24% of group revenue
Headcount5,810, net addition of 257 including MST resources
New clients added20, of which 5 have turnover above $1 billion
Fortune 1000 clients27, up two and a half times from the prior year
Attrition trendTrending down for the last three quarters
Organic revenue growth QoQLow single digit (per management)
MST Solutions expected growthHigh single digit QoQ
Top 25 US accounts contribution~70% of Americas business, consolidated with MST
UK public sector data processing win£2 cr value